Tivantinib

别名: ARQ 197

目录号：S2753 Purity: 99.65%

Tivantinib是第一个非ATP竞争性的c-Met抑制剂，在无细胞试验中K_i为0.355 μM，对Ron几乎没有作用活性，对EGFR，InsR，PDGFRα和FGFR1/4没有抑制作用。Tivantinib (ARQ 197) 可诱导G2/M期细胞阻滞和凋亡。

Tivantinib Chemical Structure

CAS: 905854-02-6

规格	价格	库存
10mM (1mL in DMSO)	958.23	现货
10mg	904.93	现货
50mg	3844.69	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.65%

99.65

Tivantinib相关产品

相关产品	SGX-523 Foretinib PHA-665752 SU11274 BMS-777607 JNJ-38877605 PF-04217903 Tepotinib Savolitinib (AZD6094) MGCD-265 analog Golvatinib (E7050) Merestinib (LY2801653) MK-2461 NPS-1034 AMG 337 Sodium L-ascorbyl-2-phosphate BMS-794833 NVP-BVU972 S49076	点击展开
相关化合物库	激酶抑制剂库酪氨酸激酶抑制剂分子库 PI3K/Akt 抑制剂库细胞周期化合物库血管生成相关化合物库	点击展开

细胞实验数据示例

细胞系	实验类型	给药浓度	活性描述
MNK-45	Kinase assay	~10 μM	inhibits c-Met phosphorylation and downstream c-Met signaling pathways
HT29	Kinase assay	~10 μM	inhibits c-Met phosphorylation and downstream c-Met signaling pathways
MDA-MB-231	Kinase assay	~10 μM	inhibits c-Met phosphorylation and downstream c-Met signaling pathways
NCI-H441	Kinase assay	~10 μM	inhibits c-Met phosphorylation and downstream c-Met signaling pathways
SK-MEL-28	Growth inhibitory assay	33 μM	IC50>33 μM
NCI-H661	Growth inhibitory assay	33 μM	IC50>33 μM
NCI-H446	Growth inhibitory assay	33 μM	IC50=7 μM
MDA-MB-231	Growth inhibitory assay	33 μM	IC50=0.55 μM
DLD-1	Growth inhibitory assay	33 μM	IC50=0.53 μM
A549	Growth inhibitory assay	33 μM	IC50=0.59 μM
SK-OV-3	Growth inhibitory assay	33 μM	IC50=0.66 μM
NCI-H460	Growth inhibitory assay	33 μM	IC50=0.6 μM
A375	Growth inhibitory assay	33 μM	IC50=0.42 μM
NCI-H441	Growth inhibitory assay	33 μM	IC50=0.3 μM
HT29	Growth inhibitory assay	33 μM	IC50=0.49 μM
MKN-45	Growth inhibitory assay	33 μM	IC50=0.58 μM
HT29	Apoptosis assay	~10 μM	significantly induces apoptosis by 80-90%.
MKN-45	Apoptosis assay	~10 μM	significantly induces apoptosis by 80-90%.
MDA-MB-231	Apoptosis assay	~10 μM	modestly induces apoptosis by 35%.
MDA-MB-231/TGL	Growth inhibitory assay	~100 μM	GI50=1.2 μM
1833/TGL	Growth inhibitory assay	~100 μM	GI50=3.7 μM
EBC1	Cytotoxic assay	~10 μM	inhibits the cell growth.
SNU638	Cytotoxic assay	~10 μM	inhibits the cell growth.
A549	Cytotoxic assay	~10 μM	not affect
H460	Cytotoxic assay	~10 μM	not affect
HCC827	Cytotoxic assay	~10 μM	not affect
A549	Function assay	10 μM	disrupts microtubule
EBC1	Function assay	10 μM	disrupts microtubule
H460	Function assay	10 μM	inhibits tubulin polymerization
K562/VCR	Cytotoxic assay	~10 μM	shows cytotoxic activity
CEM/VBL	Cytotoxic assay	~10 μM	shows cytotoxic activity
U266	Cytotoxic assay	~3 μM	IC50=1.1 μM
OPM-2	Cytotoxic assay	~3 μM	IC50=1.8 μM
MM.1S	Cytotoxic assay	~3 μM	IC50=1.6 μM
MM.1R	Growth inhibitory assay	3 μM	inhibits cell growth by 49%
RPMI-8226	Cytotoxic assay	~3 μM	IC50=0.9 μM
ANBL-6	Cytotoxic assay	1 μM	induces cell death by more than 50%
ANLB-6/V10R	Cytotoxic assay	1 μM	induces cell death by more than 50%
KAS-6/1	Cytotoxic assay	1 μM	induces cell death by more than 50%
KAS-6/V10R	Cytotoxic assay	1 μM	induces cell death by more than 50%
KAS-6/R10R	Cytotoxic assay	1 μM	induces cell death by more than 50%
8226/S	Growth inhibitory assay	3 μM	inhibits cell growth by 54%
8226/LR-5	Growth inhibitory assay	3 μM	inhibits cell growth by 54%
Huh7	Cytotoxic assay	~4.8 μM	IC50=9.9 nM
Hep3B	Cytotoxic assay	~4.8 μM	IC50=448.7 nM
HepG2	Cytotoxic assay	~4.8 μM	IC50=139.77 nM
Chang	Cytotoxic assay	~4.8 μM	IC50=448.7 nM
Huh7	Function assay	1.6 μM	causes a G2/M cell cycle arrest
Hep3B	Function assay	1.6 μM	causes a G2/M cell cycle arrest
HepG2	Function assay	1.6 μM	causes a G2/M cell cycle arrest
Chang	Function assay	1.6 μM	causes a G2/M cell cycle arrest
MHCC97L	Growth inhibitory assay	~10 μM	IC50=315 nM
MHCC97H	Growth inhibitory assay	~10 μM	IC50=368 nM
Huh7	Growth inhibitory assay	~10 μM	IC50=265 nM
HepG2	Growth inhibitory assay	~10 μM	IC50=392 nM
MHCC97L	Function assay	1 μM	induces microtubules depolymerization
Huh7	Function assay	1 μM	induces microtubules depolymerization
MHCC97L	Apoptosis assay	1 μM	induces apoptosis
Huh7	Apoptosis assay	1 μM	induces apoptosis
C3H 10T1/2 mouse fibroblasts	Kinase assay	25 μM	reduces Histone H3 and H4 acetylation levels
H23	Growth inhibitory assay	25 μM	significantly inhibits cell growth.
WM35	Growth inhibitory assay	10 μM	significantly inhibits cell growth.
NIH 3T3	Growth inhibitory assay	10 μM	does not have a significant inhibitory effect
H838	Growth inhibitory assay	10 μM	does not have a significant inhibitory effect
H1395	Growth inhibitory assay	10 μM	does not have a significant inhibitory effect
Quiescent S2	Kinase assay	30 μM	completely abrogates TSA-induced hyperacetylation of H3K4me3 histones
PC3	Apoptosis assay	20 μM	induces apoptosis
Du145	Apoptosis assay	20 μM	induces apoptosis
LNCaP	Apoptosis assay	20 μM	induces apoptosis
LAPC-4	Apoptosis assay	20 μM	induces apoptosis
LNCaP	Function assay	20 μM	decreases PSA secretion and p65 expression levels
LAPC-4	Function assay	20 μM	decreases PSA secretion and p65 expression levels
Kasumi-1	Growth inhibitory assay	~50 μM	inhibits cell proliferation
SKNO-1	Growth inhibitory assay	~50 μM	inhibits cell proliferation
Kasumi-1	Kinase assay	~10 μM	reduces expression of acetylated histone H3, c-kit and bcl-2
SKNO-1	Kinase assay	~10 μM	reduces expression of acetylated histone H3, c-kit and bcl-2
A549	Function assay	10 μM	enhances mitotic catastrophe
NRK-52E	Function assay	10 μM	inhibits Ang II-induced STAT3 nuclear translocation and the expression of TGF-β1, collagen IV and fibronectin
PC12	Growth inhibitory assay	~12.5 μM	prevents TSA-induced neurite formation
A549	Function assay	~50 μM	affects the viral life cycle and host response
RAW264.7	Function assay	~30 μM	reduces pro-inflammatory gene expression
MEMM	Kinase assay	15 µM	decreases acetylation of histone H3
MEMM	Growth inhibitory assay	~20 µM	inhibits cell proliferation
MEMM	Apoptosis assay	15 µM	induces the presence of the apoptosis protein, cleaved Caspase-3
T47D	Growth inhibitory assay	10 μM	IC50=72 nM
ZR-75-1	Growth inhibitory assay	10 μM	IC50=79 nM
BT474	Growth inhibitory assay	10 μM	IC50=86 nM
HCC1954	Growth inhibitory assay	10 μM	IC50=119 nM
MDA-MB-453	Growth inhibitory assay	10 μM	IC50=975 nM
MDA-MB-468	Growth inhibitory assay	10 μM	IC50=3208 nM
SkBr3	Growth inhibitory assay	10 μM	IC50>10,000 nM
MDA-MB-231	Growth inhibitory assay	10 μM	IC50>10,000 nM
HCT116	Growth inhibitory assay	10 μM	IC50=5836 nM
HT29	Growth inhibitory assay	10 μM	IC50>10,000 nM
HFF	Growth inhibitory assay	10 μM	IC50=7615 nM
HN5	Growth inhibitory assay	10 μM	IC50>10,000 nM
786-0	Growth inhibitory assay	10 μM	IC50=4009 nM
H157	Growth inhibitory assay	10 μM	IC50=2642 nM
NCI-H460	Growth inhibitory assay	10 μM	IC50>2,500 nM
SKOV-3	Growth inhibitory assay	10 μM	IC50=2126 nM
OVCAR-3	Growth inhibitory assay	10 μM	IC50=2918 nM
BXPC3	Growth inhibitory assay	10 μM	IC50=3141 nM
MiaPaCa	Growth inhibitory assay	10 μM	IC50=5433 nM
PANC-1	Growth inhibitory assay	10 μM	IC50=8681 nM
LNCaP	Growth inhibitory assay	10 μM	IC50=147 nM
DU145	Growth inhibitory assay	10 μM	IC50=3812 nM
PC3	Growth inhibitory assay	10 μM	IC50>10,000 nM
BT474	Kinase assay	10 μM	inhibits pGSK3β with IC50 of 160 nM
786-0	Kinase assay	10 μM	inhibits pGSK3β with IC50 of 150 nM
LNCaP	Kinase assay	10 μM	inhibits pGSK3β with IC50 of 43 nM
PC3	Kinase assay	10 μM	inhibits pGSK3β with IC50 of 49 nM
KARPAS-231	Growth inhibitory assay	10 μM	EC50=41 nM
CCRFSB	Growth inhibitory assay	10 μM	EC50=155 nM
SUP B15	Growth inhibitory assay	10 μM	EC50=197 nM
SD-1	Growth inhibitory assay	10 μM	EC50=320 nM
RS4;11	Growth inhibitory assay	10 μM	EC50=654 nM
MN-60	Growth inhibitory assay	10 μM	EC50=3602 nM
Tanoue	Growth inhibitory assay	10 μM	EC50=4517 nM
RCH-ACV	Growth inhibitory assay	10 μM	EC50=152 nM
SEM	Growth inhibitory assay	10 μM	EC50=202 nM
KASUMI-2	Growth inhibitory assay	10 μM	EC50=225 nM
REH	Growth inhibitory assay	10 μM	EC50=288 nM
697	Growth inhibitory assay	10 μM	EC50=338 nM
NALM-6	Growth inhibitory assay	10 μM	EC50=421 nM
MHH-CALL–3	Growth inhibitory assay	10 μM	EC50=812 nM
MHH-CALL–2	Growth inhibitory assay	10 μM	EC50=2114 nM
J.GAMMA-1	Growth inhibitory assay	10 μM	EC50=65 nM
JR45.01	Growth inhibitory assay	10 μM	EC50=68 nM
A3	Growth inhibitory assay	10 μM	EC50=69 nM
I 2.1	Growth inhibitory assay	10 μM	EC50=73 nM
MOLT-3	Growth inhibitory assay	10 μM	EC50=74 nM
P116	Growth inhibitory assay	10 μM	EC50=78 nM
J.Cam1.6	Growth inhibitory assay	10 μM	EC50=79 nM
I 9.2	Growth inhibitory assay	10 μM	EC50=80 nM
LOUCY	Growth inhibitory assay	10 μM	EC50=117 nM
J.RT3-T3.5	Growth inhibitory assay	10 μM	EC50=123 nM
800000	Growth inhibitory assay	10 μM	EC50=163 nM
Jurkat	Growth inhibitory assay	10 μM	EC50=225 nM
MOLT-4	Growth inhibitory assay	10 μM	EC50=232 nM
Molt-16	Growth inhibitory assay	10 μM	EC50=241 nM
CEM/C3	Growth inhibitory assay	10 μM	EC50=257 nM
CEM/C2	Growth inhibitory assay	10 μM	EC50=271 nM
CCRFCEM	Growth inhibitory assay	10 μM	EC50=327 nM
CEM/C1	Growth inhibitory assay	10 μM	EC50=382 nM
SUPTI[VB]	Growth inhibitory assay	10 μM	EC50=619 nM
CCRF–HSB-2	Growth inhibitory assay	10 μM	EC50=2117 nM
I 2.1	Apoptosis assay	10 μM	induces apoptosis
I 9.2	Apoptosis assay	10 μM	induces apoptosis
A3	Apoptosis assay	10 μM	induces apoptosis
RD	Growth inhibitory assay	10 μM	IC50>10 μM
Rh41	Growth inhibitory assay	10 μM	IC50=33.8 nM
Rh18	Growth inhibitory assay	10 μM	IC50=303 nM
Rh30	Growth inhibitory assay	10 μM	IC50=4.81 μM
BT-12	Growth inhibitory assay	10 μM	IC50>10 μM
CHLA-266	Growth inhibitory assay	10 μM	IC50=1.22 μM
TC-71	Growth inhibitory assay	10 μM	IC50=2.52 μM
CHLA-9	Growth inhibitory assay	10 μM	IC50=591 nM
CHLA-10	Growth inhibitory assay	10 μM	IC50=102 nM
CHLA-258	Growth inhibitory assay	10 μM	IC50=1.05 μM
GBM2	Growth inhibitory assay	10 μM	IC50=9.15 μM
NB-1643	Growth inhibitory assay	10 μM	IC50=5.4 μM
NB-Ebc1	Growth inhibitory assay	10 μM	IC50>10 μM
CHLA-90	Growth inhibitory assay	10 μM	IC50>10 μM
CHLA-136	Growth inhibitory assay	10 μM	IC50>10 μM
NALM-6	Growth inhibitory assay	10 μM	IC50=265 nM
COG-LL-317	Growth inhibitory assay	10 μM	IC50=6.49 nM
RS4;11	Growth inhibitory assay	10 μM	IC50=147 nM
MOLT-4	Growth inhibitory assay	10 μM	IC50=40 nM
CCRF-CEM	Growth inhibitory assay	10 μM	IC50=268 nM
Kasumi-1	Growth inhibitory assay	10 μM	IC50=107 nM
Karpas-299	Growth inhibitory assay	10 μM	IC50=2.93 μM
Ramos-RA1	Growth inhibitory assay	10 μM	IC50=7.35 μM
H1299	Kinase assay	10 μM	inhibits IKBKE-induced Akt Activation
HPMCs	Function assay		reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells
点击查看更多细胞系数据

生物活性

产品描述

特性

ARQ-197是第一个应用到晚期人类临床试验的c-Met选择性抑制剂。

靶点

c-Met ^[1]
(Cell-free assay)

0.355 μM(Ki)

体外研究(In Vitro)
体外研究活性	ARQ-197抑制HGF/c-met诱导的细胞反应。ARQ-197具有抗肿瘤活性，抑制A549, DBTRG和NCI-H441细胞增殖，IC50分别为0.38, 0.45, 0.29 μM。用ARQ-197处理，导致MAPK信号级联放大磷酸化降低，且阻断入侵和迁移。此外,没有内源性c-Met表达的NCI-H661细胞中c-Met异常表达，形成一种入侵表现型，也被ARQ-197抑制。加入浓度不断增加的ARQ-197不会明显影响ATP的K_m值，但是用0.5 μM ARQ-197处理c-Met，则降低c-Met的V_max值，降低3倍。ARQ-197降低V_max而不影响ATP的K_m值说明ARQ-197抑制c-Met是非ATP竞争抑制，也说明ARQ-197具有高度激酶选择性。ARQ-197抑制人类重组c-Met，具有恒定的K_i值，为355 nM。虽然使用过的ATP最高浓度为200 μM, 但是当ATP浓度为1 mM时，ARQ-197抑制c-Met效果不会降低。ARQ-197抑制c-Met磷酸化，且阻断下游c-Met信号通路。ARQ-197阻断组成型和配体调节的c-Met自磷酸化，通过增强c-Met活性, 反过来抑制下游c-Met效应器。ARQ-197作用于表达c-Met的人类癌细胞包括HT29, MKN-45, 和MDA-MB-231细胞，诱导caspase依赖的凋亡。^[1]
激酶实验	体外c-Met SDS-PAGE 激酶试验
激酶实验	100 ng重组c-Met蛋白和浓度不断增高ARQ-197在室温下预温育30分钟。随后，100 μM 聚Glu-Tyr底物和含5 μCi[γ-³²P]ATP的不同浓度ATP加到反应混合物中。反应在室温下进行5分钟，然后加入5 μL SDS-聚丙烯酰胺胶,降低样本缓冲液。上样到7.5%丙烯酰胺胶上，进行SDS-PAGE。通过放射自显影观察到磷酸化的聚Glu-Tyr底物。通过光密度法测定c-Met活性。
细胞实验	细胞系	T29, MKN-45和MDA-MB-231细胞
	浓度	0.03-10 μM
	孵育时间	24, 32,和48细胞
	方法	HT29,MKN-45,和MDA-MB-231细胞按每孔5×10³个接种在96孔板上，孔中有含10% FBS的培养基，在黑暗中过夜处理。第二天,用浓度不断增长的ARQ-197 (0.03-10 μM)在37^oC下处理细胞24,32,和48 小时。ARQ-197处理后，移除培养基，细胞在含2 μg/mL Hoescht 33342的标签溶液(10 mM HEPES, 140 mM NaCl,和6 mM CaCl₂)中温育至少10分钟, 用Annexin V-FITC(稀释500倍)和1 μg/mL碘化丙锭染色。进行高含量的图像采集和分析，每孔获取四个图像。 4,6-二脒基-2-苯基吲哚, FITC, 和罗丹明通道分别在16.7 ms/10%, 500 ms/35% ,和300 ms/30% 进行处理。处理图像，测定每组通道和每种情况下的阳性细胞数。此外,在有或者没有25,50,和100 μM ZvAD-FMK存在条件下，HT29细胞用浓度不断增加的ARQ-197处理32小时。所有实验重复进行三次。测定抑制c-Met是否导致细胞凋亡，当使用siRNA分解磷酸甘油醛脱氢酶(GAPDH)和c-Met时ARQ-197的作用效果。HT29, MKN-45,和MDA-MB-231细胞转染无靶点对照 siRNA, GAPDH靶点对照siRNA, 或met靶点siRNA。3天后，使用特点抗体测定c-Met, GAPDH, 和 β-actin表达水平。为了测定caspase依赖是否影响，HT29, MKN-45, 和MDA-MB-231细胞转染 met靶点 siRNA，进行2天。然后在有或没有浓度不断增高的ZvAD-FMK存在下再温育1天。无靶点siRNA和GAPDH siRNA也转染，作为对照。然后用Annexin V-FITC和碘化丙锭进行细胞染色,测定凋亡细胞百分数。
实验图片	检测方法	检测指标	实验图片	PMID
	Western blot	cMET / p-cMET / p-AKT / p-ERK / p-rpS6		23022995
	Growth inhibition assay	Cell viability		23598276

体内研究(In Vivo)
体内研究活性	ARQ-197处理 HT29,MKN-45,和MDA-MB-231三种移植瘤模型，肿瘤生长率分别降低66%,45%,和79%。ARQ-197按200 mg/kg剂量口服给药这三种移植瘤模型，显示体重都没有明显改变。药效学方面，ARQ-197作用于人类结肠移植瘤HT29，强抑制c-Met的磷酸化, ARQ-197按200 mg/kg剂量单独口服给药24小时后，c-Met自磷酸化强烈下降。总之，ARQ-197抑制人类c-Met依赖的移植瘤生长。^[1]
动物实验	Animal Models	携带HT29,MKN-45,或MDA-MB-231移植瘤的无胸腺裸鼠
	Dosages	200 mg/kg
	Administration	口服处理

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
临床试验信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT02150733	Completed	Hepatic Impairment\|Solid Tumor\|Cancer	Daiichi Sankyo\|Medpace Inc.	April 2014	Phase 1
NCT01892527	Completed	Colorectal Cancer Metastatic\|C-met Overexpression	Armando Santoro MD\|Istituto Clinico Humanitas	March 2013	Phase 2
NCT02049060	Completed	Malignant Pleural Mesothelioma\|Nonsquamous Nonsmall Cell Neoplasm of Lung	Armando Santoro MD\|Istituto Clinico Humanitas	January 2013	Phase 1\|Phase 2
NCT01755767	Completed	Hepatocellular Carcinoma	Daiichi Sankyo\|ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)	December 27 2012	Phase 3

参考文献
https://pubmed.ncbi.nlm.nih.gov/20484018/ https://pubmed.ncbi.nlm.nih.gov/18511928/

参考文献

https://pubmed.ncbi.nlm.nih.gov/20484018/
https://pubmed.ncbi.nlm.nih.gov/18511928/

化学信息&溶解度

分子量	369.42	分子式	C₂₃H₁₉N₃O₂
CAS号	905854-02-6	SDF	Download Tivantinib SDF
Smiles	C1CC2=C3C(=CC=C2)C(=CN3C1)C4C(C(=O)NC4=O)C5=CNC6=CC=CC=C65
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 73 mg/mL ( (197.6 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : 35 mg/mL (94.74 mM)

Water : Insoluble

DMSO : 73 mg/mL ( (197.6 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解配方批次：现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂				动物体内配方计算器
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。
澄清溶液	5%DMSO 1 Corn oil 该配方已经过Selleck实验室实测。如果上述溶解方案不能满足您的需求，可联系Selleck销售提供定制化测试。	3.500mg/ml (9.47mM)	以 1 mL 工作液为例，取50μL70mg/ml的澄清DMSO储备液加到950μL玉米油中，混合均匀。工作液请现配现用！

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

常见问题及建议解决方法

问题 1:
Are there any other solutions (apart from DMSO) I can dissolve S2753 for in vivo experiment?

回答：
S2753 Tivantinib (ARQ 197) can be dissolved in 1% methylcellulose at15 mg/ml as a suspension.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):